The University of Iowa commercialization GAP fund is now available to faculty on a rolling basis, year-round.
Hillel Haim, University of Iowa assistant professor of microbiology, is working on establishing new approaches to inactivate human immunodeficiency virus type 1 (HIV-1) and to increase its sensitivity to antibodies elicited by vaccines.
When an individual with epilepsy has a seizure, he or she needs quick delivery of an anticonvulsant drug. That’s why Max Baker, UI associate professor in the anesthesia department, has been working for two years on a rapid, easy-to-use, buccal drug delivery device for the urgent treatment of seizures.
Five-hundred meters underwater in the south Pacific, a marine sponge contains a compound with unique anti-cancer properties. The only problem is supply. The sponge is not quite easily accessible, and when it is found, it typically doesn’t yield enough material to study.
Brad Amendt, UI professor of anatomy and cell biology, is about to go commercial with his new class of microRNA inhibitors to be used in tissue reprogramming, tissue engineering, and bone formation. His team has developed a new plasmid based series of microRNA reagents.
The University of Iowa’s UI Ventures program has awarded $750,000 in GAP funding to 11 awardees for FY2015, helping faculty and other researchers bridge the cost of translating their work into commercial products, services, and businesses.